RICHMOND, VA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE CARDIAC NEURODEVELOPMENTAL OUTCOME COLLABORATIVE, founded in 2015, is a small nonprofit in the Diseases & Disorders sector that reported $319K in total revenue in fiscal year 2025. The organization ran a surplus of $117K, a strong 37% operating margin.
THE CNOC IS A NOT-FOR-PROFIT ORGANIZATION ESTABLISHED TO DETERMINE AND IMPLEMENT BEST PRACTICES OF NEURODEVELOPMENTAL AND PSYCHOSOCIAL SERVICES FOR INDIVIDUALS WITH PEDIATRIC AND CONGENITAL HEART DISEASE AND THEIR FAMILIES THROUGH CLINICAL, QUALITY IMPROVEMENT, AND RESEARCH INITIATIVES.
PROVIDE TRAINING, EDUCATION, AND RELEVANT INFORMATION TO MEMBERS THROUGH PUBLICATIONS, THE ANNUAL SYMPOSIUM, AND THE WEBSITE AND TO FOSTER COMMUNITY OUTREACH THROUGH THESE SAME FORUMS.
CNOC'S NEURODEVELOPMENTAL CORE LAB (NDC) AND DATA ANALYSIS CORE (DAC) ARE RESEARCHING THE DEVELOPMENT OF INFANTS, TODDLERS AND PRESCHOOLERS WHO HAVE UNDERGONE NEONATAL CARDIAC SURGERY USING A LIMITED...
CNOC'S NEURODEVELOPMENTAL CORE LAB (NDC) AND DATA ANALYSIS CORE (DAC) ARE RESEARCHING THE DEVELOPMENT OF INFANTS, TODDLERS AND PRESCHOOLERS WHO HAVE UNDERGONE NEONATAL CARDIAC SURGERY USING A LIMITED LIST OF DEMOGRAPHIC, NEURODEVELOPMENTAL, MEDICAL HISTORY AND SURGICAL VARIABLES. AS INITIAL AIMS ARE ACHIEVED, NEURODEVELOPMENTAL TESTING OUTCOMES, QUALITY OF LIFE OUTCOMES AND MEDICAL HISTORY DATA WILL BE ADDED TO THESE EFFORTS.
THE PURPOSE OF THE CNOC INVESTIGATOR AWARD IS TO PROVIDE FUNDING SUPPORT FOR CNOC MEMBERS TO LEVERAGE THE CNOC INFRASTRUCTURE TO CONDUCT RESEARCH AND/OR QUALITY IMPROVEMENT SCIENCE AIMED AT IMPROVING...
THE PURPOSE OF THE CNOC INVESTIGATOR AWARD IS TO PROVIDE FUNDING SUPPORT FOR CNOC MEMBERS TO LEVERAGE THE CNOC INFRASTRUCTURE TO CONDUCT RESEARCH AND/OR QUALITY IMPROVEMENT SCIENCE AIMED AT IMPROVING NEURODEVELOPMENTAL, PSYCHOSOCIAL OUTCOMES, AND/OR QUALITY OF LIFE FOR CHILDREN AND FAMILIES AFFECTED BY CONGENITAL HEART DISEASE (CHD).
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2025 | 2024 | Change | |
|---|---|---|---|
| Revenue | $319,183 | $322,742 | 0.0% |
| Expenses | $202,446 | $173,063 | +0.2% |
| Net Income | $116,737 | $149,679 | -0.2% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| CYNTHIA ORTINAU | CO-CHAIR | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| NADINE KASPARIAN | CO-CHAIR | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| SAMANTHA C BUTLER | CO-VICE CHAIR | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| CAITLIN ROLLINS | CO-VICE CHAIR | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| SARAH KELLY | SECRETARY | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| ANJALI SADHWANI | TREASURER | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| SHABNAM PEYVANDI | IMMEDIATE PAST CHAIR | 2.00 |
Director
|
$0 | $0 | $0 |
| KELLY WOLFE | IMMEDIATE PAST CHAIR | 2.00 |
Director
|
$0 | $0 | $0 |
| SHERRILL CAPRAROLA | MEMBER-AT-LARGE | 2.00 |
Director
|
$0 | $0 | $0 |
| BRUNA SCHNEIDER | MEMBER-AT-LARGE | 2.00 |
Director
|
$0 | $0 | $0 |
| FRANK CASEY | EUROPEAN LIAISON | 2.00 |
Director
|
$0 | $0 | $0 |
| ERIN BECKEMEIER | PATIENT/PARENT REP | 2.00 |
Director
|
$0 | $0 | $0 |
| GINNIE ABARBANELL | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| LAURENCE BEAULIEU-GENEST | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| KIMBERLEY HEINRICH | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| CORINNE ANTON | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| GINA BOUCHER | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| RICHARD JAMES | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| JUSTIN ELHOFF | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| CARISSA OSTROM | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| CHETNA PANDE | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| ANDREA SMITH | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| ELIZABETH WILLEN | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| SARAH PLUMMER | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| ERICA SOOD | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| AMANDA SHILLINGFORD | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| ALEX TAN | STEERING COMMITTEE MEMBER | 2.00 |
Director
|
$0 | $0 | $0 |
| STEWART HINCKLEY | EXECUTIVE DIRECTOR | 3.00 |
Officer
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $319,183 | $202,446 | $816,043 | $116,737 |
| 2024 | $322,742 | $173,063 | $655,327 | $149,679 |
| 2023 | $208,879 | $98,798 | $485,511 | $110,081 |
| 2022 | $297,250 | $256,758 | $426,180 | $40,492 |
| 2021 | $257,405 | $190,672 | $328,730 | $66,733 |
| 2020 | $224,395 | $185,298 | $300,795 | $39,097 |
| 2019 | $263,108 | $274,242 | $247,962 | $-11,134 |
| 2018 | $324,524 | $248,814 | $251,637 | $75,710 |
Compare THE CARDIAC NEURODEVELOPMENTAL OUTCOME COLLABORATIVE with other nonprofits in Virginia and across the country.